Haiyue You
No ORCID on file
· 1 paper in corpus
review
2026
BACKGROUND: The clinical benefit of immunotherapy in ovarian cancer (OC) remains limited. The primary reason is not simply a lack of immune activation, but rather the marked spatiotemporal heterogeneity of the tumour immune microenvironment…